High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Arm Holdings PLC CEO Rene Haas said artificial intelligence could help find a cure for cancer within our lifetime, but warned that chip shortages are limiting the expansion of AI infrastructure. Haas said AI could eventually solve complex problems in...
Moderna’s upsized note offering quickly followed a big win in a crucial study. Elsewhere, a biotech’s shares tumbled after study data were “inadvertently” published ahead of a medical meeting.
Nvidia Corp‘s GPUs have become the backbone of artificial intelligence, but they won’t be enough to determine the winners in AI-driven drug discovery. In an exclusive email interview with Benzinga, Generate Biomedicines co-founder and CTO Gevorg Grigoryan said advanced computing...
Generate Biomedicines has delivered a 27.6% gain year to date, yet on broad valuation checks the stock screens as expensive rather than a clear bargain. With the post IPO lock up expiration drawing attention to trading activity, investors are weighing whether that strong run leaves limited room for disappointment. Year to date, the stock is up 27.6%, which puts extra focus on whether recent enthusiasm is already reflected in the price. The upcoming lock up expiry can keep trading active,...
Shares of Generate Biomedicines Inc (NASDAQ:GENB) jumped more than 20% on Tuesday as investors positioned ahead of the expiration of the company's post-IPO lock-up period. The lock-up, which ends Wednesday, will free company insiders, early investors and major shareholders to sell shares...
Generate Biomedicines focuses on AI-enabled drug discovery.
Jersey Mike’s Subs, with its 5.96% stock-price decline Thursday, is hardly alone in having a first-day share slide. This year, shares for hedge fund Pershing Square, nuclear fuel company Standard Nuclear and biotech firm Generate Biomedicines fell 18%, 18% and 21% respectively on their first trading days, according to Dealogic.
Ark Invest's top investor is adding to stocks that went public over the past year.
Generate Biomedicines, Inc. (NASDAQ:GENB) is one of the 12 Best AI Drug Discovery Stocks Hedge Funds Are Loading Up On. On May 14, Morgan Stanley increased its price objective on Generate Biomedicines, Inc. (NASDAQ:GENB) to $22 from $20. The firm maintained an “Overweight” rating on the shares. Separately, Generate Biomedicines, Inc. (NASDAQ:GENB)’s GB-0895 (anti-TSLP) program […]
Recent trading snapshot and business context Generate Biomedicines (GENB) has drawn investor interest after a mixed stretch in the stock, with a small gain of 0.2% over the past day set against a decline of 9.7% over the past week. Over the past month the stock is roughly flat, while the past 3 months show a gain of 10.0%. This recent trading context sits alongside a market value of about US$1.68b and a share price of US$13.12 at the last close. See our latest analysis for Generate...
This biotechnology firm leverages machine learning to design novel protein therapeutics targeting unmet medical needs.
Nvidia’s backing highlights growing confidence in AI-powered biotech stocks.
Generate Biomedicines, Inc. (NASDAQ:GENB) is one of the best low priced biotech stocks to invest in. On April 13, H.C. Wainwright initiated coverage of Generate Biomedicines, Inc. (NASDAQ:GENB) with a Buy rating, setting a $16 price target. The firm told investors in a research note that the stock has fallen over 20% even as GB-0895 advanced into […]
Generate Biomedicines: Recent Trading Moves And Core Business Snapshot Generate Biomedicines (GENB) has seen recent share price pressure, with a 10% decline over the past week and a similar move over the past month, bringing the latest close to US$11.21. For context, the company reports revenue of US$31.893 million alongside a net loss of US$249.523 million, reflecting the costs of developing its generative biology platform and early stage pipeline of protein based therapeutics. See our...
Health care stocks rose late Friday afternoon, with the NYSE Health Care Index adding 1.3% and the S
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
